J 2020

In Ph+BCR-ABL1(P210+) acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent

BACCARANI, M., I. IACOBUCCI, S. CHIARETTI, R. FOA, P. BALASUBRAMANIAN et. al.

Basic information

Original name

In Ph+BCR-ABL1(P210+) acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent

Authors

BACCARANI, M. (guarantor), I. IACOBUCCI, S. CHIARETTI, R. FOA, P. BALASUBRAMANIAN, E. PAIETTA, L. FORONI, S. JEROMIN, B. IZZO, O. SPINELLI, N. VARMA, S. MENIF, C. TERRAGNA, T. SETH, A. BIDET, D. CORIU, F. LUNGHI, Jiří MAYER (203 Czech Republic, belonging to the institution), B. SCAPPINI, S. LANGABEER, J. MAIER, E. BURT, A. CANDONI, F. ALBANO, M. LUPPI, I. ZUPAN, T. LION, R. ZADRO, F. DI RAIMONDO, B. POOPAK, G. REGE-CAMBRIN, M. ANNUNZIATA, A. AYALA, V. SALINAS-VIEDMA, A. INES PADO, B. MILNER, S. GALIMBERTI, J. JANSSEN, V. POLLI, L. COMBA, B. BORSELLINO, O. ANNIBALI, M. CRUGNOLA and F. PASSAMONTI

Edition

Leukemia, London, Nature Publishing Group, 2020, 0887-6924

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 11.528

RIV identification code

RIV/00216224:14110/20:00118153

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1038/s41375-019-0591-9

UT WoS

000519468700024

Keywords in English

acute lymphoblastic leukemia

Tags

14110212, rivok

Tags

International impact, Reviewed
Změněno: 11/2/2021 13:55, Mgr. Tereza Miškechová

Abstract

V originále

Philadelphia-chromosome positive (Ph+), BCR-ABL1+ acute lymphoblastic leukemia (ALL) is a distinct entity that is characterized by specific genomic alterations, low sensitivity to chemotherapy, unstable responsiveness to tyrosine kinase inhibitors (TKIs), and a poor prognosis.
Displayed: 15/11/2024 17:42